Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

This study has been terminated.
(Poor accrual)
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT01350258
First received: May 4, 2011
Last updated: October 21, 2014
Last verified: October 2014
  Purpose

This is a research study involving the treatment of patients with hematological cancers with allogeneic (cells from a donor) hematopoietic stem cell transplant (HSCT). HSCT is often referred to as bone marrow transplant. Patients who are not expected to have long term survival after conventional therapy will undergo HSCT as a curative therapy after receiving front line therapy for their disease. This project is based on an HSCT approach that has been used at TJU since 2006 with the goal of optimizing this type of treatment further. In this new study, the investigators will substitute the chemotherapy agent, Melphalan (Mel), for cyclophosphamide (CY). Cyclophosphamide was used in the original trial. The research question is whether side effects are less using Mel and if donor T cells can be made tolerant to the recipient with the use of Mel. The proposed study is also more specific in terms of performance status and organ function entry criterion. The investigators observed in the original trial that patients with poor performance upon admission for transplant did not have as good outcomes.

Because many older patients are treated according to this type of transplant, the chemotherapy and radiation used are less intensive than other types of transplant. The name for this in the transplant field is a reduced intensity hematopoietic stem cell transplant. The abbreviations most used in this document are RIC for reduced intensity conditioning, HSCT which refers to the transplant itself, and MEL which refers to the drug, Melphalan.


Condition Intervention Phase
Hematologic Malignancies
Acute Leukemia
Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes.
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Myeloma
Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Melphalan
Device: Hematopoietic stem cell transplantation (HSCT)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization

Resource links provided by NLM:


Further study details as provided by Thomas Jefferson University:

Primary Outcome Measures:
  • Phase 1: Defined Dose of Melphalan (MEL) [ Time Frame: 100 days post-transplant ] [ Designated as safety issue: Yes ]
    To define the dose of MEL required for the establishment of peripheral T cell tolerance with concomitant immune reconstitution.

  • Phase 2: Non-Relapse Mortality (NRM) [ Time Frame: 100 days post-treatment ] [ Designated as safety issue: No ]
    To evaluate the 100 day non-relapse mortality (NRM) rate in patients undergoing HSCT treated on this successor TJU 2 Step RIC haploidentical regimen and compare it with that of the initial regimen.


Secondary Outcome Measures:
  • Relapse Rate [ Time Frame: At 1 and 3 years ] [ Designated as safety issue: No ]
    To compare relapse rates in patients undergoing HSCT treated on this successor TJU 2 Step RIC haploidentical regimen and compare it with that of the initial regimen.

  • GVHD Incidence and Severity [ Time Frame: At 1 and 3 years ] [ Designated as safety issue: Yes ]
    To determine the incidence and severity of graft-versus-host disease (GVHD) in patients undergoing treatment on this regimen using MEL for T cell tolerization as well as tacrolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis.

  • Engraftment Rate and Lymphoid Reconstitution [ Time Frame: 100 days post-transplant ] [ Designated as safety issue: Yes ]
    To evaluate engraftment rates and lymphoid reconstitution in patients treated on this trial.

  • Overall Survival [ Time Frame: At 1 and 3 years ] [ Designated as safety issue: No ]
    To assess overall survival in patients undergoing HSCT treated on this trial.


Enrollment: 8
Study Start Date: April 2011
Study Completion Date: August 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Transplant Treatment Group
All patients treated on this research study.
Drug: Fludarabine
Part of the conditioning regimen
Other Names:
  • fludarabine phosphate
  • Fludara
Drug: Thiotepa
Part of the conditioning regimen
Other Name: N,N'N'-triethylenethiophosphoramide
Radiation: Total Body Irradiation (TBI)
There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
Other Name: radiotherapy
Biological: Donor Lymphocyte Infusion (DLI)
Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
Other Name: buffy coat fusion
Drug: Melphalan
Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
Other Names:
  • MEL
  • Melphalan hydrochloride
  • Alkeran
Device: Hematopoietic stem cell transplantation (HSCT)

One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.

The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.

Other Name: CliniMACS

Detailed Description:

Twenty-nine patients in the Thomas Jefferson University (TJU) Blood and Marrow Transplantation Program have been treated on the research protocol, A Two Step Approach To Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies from HLA Partially-Matched Related Donors (TJU 2 Step RIC, TJU IRB# 06U.328) as of July, 2010. While treatment on this protocol has resulted in durable responses for many older patients and younger, heavily pretreated patients with hematological malignancies, poor performance status at the time of transplant and morbidities related to cyclophosphamide (CY) administration in the regimen have contributed to decreased survival. In addition, disease relapse after hematopoietic stem cell transplantation (HSCT) has been a major cause of mortality for those patients with disease at the time of transplant.

The objective of this research is to improve patient outcomes after treatment on the TJU 2 Step RIC protocol by refining the approach based on outcomes observed in the initial trial. More thorough assessment of performance status prior to HSCT and the substitution of the alkylating agent Melphalan (MEL) for CY to decrease CY-related toxicity while strengthening the anti-leukemic intensity of the regimen for patients with poor-risk disease will be the major strategies used to increase the efficacy of the regimen. MEL has shown efficacy against myeloid malignancies when used in conditioning in RIC HSCT. Patients with AML and MDS were the most common group treated on the initial TJU 2 Step RIC trial and also comprise the largest patient group treated in the TJU Medical Oncology Program.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Any patient with a high-risk hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. High risk is defined as:

    • Acute leukemia in 3rd or greater CR or with persistent disease
    • Myelodysplastic syndrome (MDS) other than RA or RARS subtypes.
    • Hodgkin's or Non-Hodgkin's lymphoma in 3rd or greater remission or with persistent disease.
    • Myeloma in 3rd or greater remission or with less than PR to most recent therapy.
    • Chronic myelogenous (or myeloid) leukemia (CML) resistant to STI therapy
  2. Patients must have a related donor who is at least a 4 antigen match at the HLA-A; B; C; DR loci.
  3. Patients must adequate organ function:

    • LVEF of > or = 50%
    • DLCO > or = 50% of predicted corrected for hemoglobin
    • Adequate liver function as defined by a serum bilirubin < or = 1.8, AST or ALT < or = 2.5X upper limit of normal
    • GFR of > or = 60 mL/min/1.73m2
  4. Performance status > or = 80% (TJU Karnofsky) for patients > or = 60 years old or > or = 70% for patients < 60.
  5. HCT-CI Score < or = 4 points for patients > or = 60 years old or < or = 5 points for patients < 60.
  6. Patients must be willing to use contraception if they have childbearing potential
  7. Able to give informed consent

Exclusion Criteria:

  1. Performance status < 80% (TJU Karnofsky) for patients > or = 60 years old or < 70% for patients < 60.
  2. HCT-CI Score > 4 points for patients > or = 60 years old or > 5 points for patients < 60.
  3. HIV positive
  4. Active involvement of the central nervous system with malignancy
  5. Inability to obtain informed consent
  6. Pregnancy
  7. Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder
  8. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit ant-thymocyte globulin and have an ATG level of > or = 2 ugm/ml
  9. Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol

Donor Selection All donors are selected and screened for their ability to provide adequate infection-free apheresis products for the patient in a manner that does not put the donor at risk for negative consequences. Donor selection will be in compliance with 21 CFR 1271 and TJU BMT Program SOP CP: P009.03.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01350258

Locations
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Investigators
Principal Investigator: Dolores Grosso, DNP, CRNP Thomas Jefferson University
Principal Investigator: Neal Flomenberg, MD Thomas Jefferson University
  More Information

Additional Information:
No publications provided

Responsible Party: Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT01350258     History of Changes
Other Study ID Numbers: 10D.535, 2010-40
Study First Received: May 4, 2011
Results First Received: October 21, 2014
Last Updated: October 21, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Thomas Jefferson University:
allogeneic HSCT
Hematopoietic stem cell transplantation

Additional relevant MeSH terms:
Hodgkin Disease
Leukemia
Lymphoma
Lymphoma, Non-Hodgkin
Myelodysplastic Syndromes
Neoplasms
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Precancerous Conditions
Fludarabine
Fludarabine phosphate
Melphalan
Thiotepa
Alkylating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 30, 2014